The ATG16L1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the A-549 human lung adenocarcinoma cell line, featuring disruption of the ATG16L1 gene. This heterogeneous pool of mutants provides a versatile tool for studying autophagy without clonal artifacts. The polyclonal format maintains genetic diversity while ablating functional ATG16L1 expression, suitable for pooled functional genomics, phenotypic screens, and robust population-level analyses.
A-549 cells were established from a lung adenocarcinoma tumor of a 58-year-old Caucasian male and serve as a model of alveolar basal epithelial cells. They grow adherently, retain type II pneumocyte features including surfactant production, and exhibit robust autophagic activity. Widely used in respiratory disease and cancer research, A-549 cells are well-characterized for signaling networks and drug sensitivity, offering a clinically relevant context for autophagy studies in oncogenesis and therapy resistance.
ATG16L1 is a core scaffold for the ATG12?CATG5 conjugate, essential for LC3 lipidation and autophagosome elongation. The ATG12?CATG5?CATG16L1 complex is recruited to phagophores by WIPI2, downstream of the PI3KC3?CBeclin1 lipid kinase complex, which responds to mTOR and AMPK signaling via the ULK1 initiation complex. Knockout of ATG16L1 prevents LC3-II formation and p62 degradation, blocking both canonical autophagy and related processes such as LC3-associated phagocytosis and xenophagy. This disruption can also modulate ubiquitin-dependent inflammatory pathways like NF-??B.
In A-549 cells, autophagy supports tumor maintenance and stress adaptation. ATG16L1 deficiency creates a model to study reliance on autophagic quality control and metabolic recycling. Loss of ATG16L1 is expected to impair proliferation under nutrient stress, increase chemosensitivity, and alter inflammatory cytokine secretion, mirroring its role in Crohn??s disease and inflammatory bowel disease. Thus, this polyclonal knockout pool enables dissection of autophagy-dependent mechanisms in lung cancer cell fitness and immune evasion.
Applications include mechanistic analysis of autophagosome biogenesis via LC3 immunofluorescence and flux assays with bafilomycin A1, western blotting for LC3-II/LC3-I and p62, and high-throughput drug screening for autophagy modulators. They are suited for functional genomics of ATG16L1 in Crohn??s disease, flow cytometry quantification of autophagic vesicles, and RT-qPCR of autophagy transcripts. For technical details or custom requests, contact Ascent Research.
